Summit Therapeutics Inc (NASDAQ:SMMT) currently has a daily average trading volume of 4.01M but it saw 3305186 shares traded in last market. With a market cap of 5.71B USD, the company’s current market price of $8.13 came rising about 1.12 while comparing to the previous closing price of $8.04. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.25 and as low as $1.52.
Taking a look at 20-day trading activity of Summit Therapeutics Inc (SMMT) gives us an average price of $5.53, while its current price level is -27.73% below from 52-week high level whereas it is 434.87% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $4.58 while that of 200 days or SMA-200 reads an average of $3.21. A closer look into the stock’s movement over the week reveals that its volatility is standing at 15.85% during that period while stretching the period over a month that increases to 29.18%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.97 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Citigroup which initiated the stock as “Buy” in its note to investors issued on May 07, 2024, recommending a price target of $7 for it.
Over the week, SMMT’s stock price is moving -25.55% down while it is 53.11% when we observe its performance for the past one month. Year-to-date it is 211.49% up and over the past year, the stock is showing an upside performance of 310.61%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.06 beat the consensus estimate of -0.06 for the same.
Currently, Summit Therapeutics Inc’s total number of outstanding shares is 701.66M. Company’s return on investment (ROI) stands at -77.35% and return on equity (ROE) at -130.63%. Stock’s beta reads -0.95. Stock has a price to book (P/B) ratio of 129.09. Its return on asset (ROA) is -53.77% on average.
